Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Mahé

Showing results (101-110 of 143) with videos related to

Pageof 15
Sort By:
Cancers|August 19, 2020
Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional StudyIsabelle Mahé, Ludovic Plaisance, Céline Chapelle, et al.
Clinical Cardiology|July 18, 2019
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM studyFabien Picard, Eric Van Ganse, Gregory Ducrocq, et al.
The American Journal of Medicine|February 8, 2005
Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimenVirginie Siguret, Isabelle Gouin, Matthieu Debray, et al.
Thrombosis Research|March 18, 2020
Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurelyJosé A Nieto, Damian Mora, Behnood Bikdeli, et al.
Thrombosis Research|December 9, 2023
Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolismJosé Antonio Rueda-Camino, Raquel Barba, Sonia Otálora, et al.
Stroke|June 17, 2020
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS StudyEric Van Ganse, Nicolas Danchin, Isabelle Mahé, et al.
Thrombosis and Haemostasis|September 16, 2021
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of CancerGiancarlo Agnelli, Andrés Muñoz, Laura Franco, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 28, 2022
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in FranceManon Belhassen, Olivier Hanon, Philippe Gabriel Steg, et al.
Thrombosis Research|April 16, 2018
Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort studyNick van Es, Yohei Hisada, Marcello Di Nisio, et al.
European Heart Journal|May 20, 2025
Acute pulmonary embolism: a multimarker calculator to predict short-term outcomesDavid Jiménez, Álvaro Dubois-Silva, Pablo Demelo-Rodríguez, et al.
Pageof 15

Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
Cancers|August 19, 2020
Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional StudyIsabelle Mahé, Ludovic Plaisance, Céline Chapelle, et al.
Clinical Cardiology|July 18, 2019
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM studyFabien Picard, Eric Van Ganse, Gregory Ducrocq, et al.
The American Journal of Medicine|February 8, 2005
Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimenVirginie Siguret, Isabelle Gouin, Matthieu Debray, et al.
Thrombosis Research|March 18, 2020
Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurelyJosé A Nieto, Damian Mora, Behnood Bikdeli, et al.
Thrombosis Research|December 9, 2023
Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolismJosé Antonio Rueda-Camino, Raquel Barba, Sonia Otálora, et al.
Stroke|June 17, 2020
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS StudyEric Van Ganse, Nicolas Danchin, Isabelle Mahé, et al.
Thrombosis and Haemostasis|September 16, 2021
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of CancerGiancarlo Agnelli, Andrés Muñoz, Laura Franco, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 28, 2022
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in FranceManon Belhassen, Olivier Hanon, Philippe Gabriel Steg, et al.
Thrombosis Research|April 16, 2018
Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort studyNick van Es, Yohei Hisada, Marcello Di Nisio, et al.
European Heart Journal|May 20, 2025
Acute pulmonary embolism: a multimarker calculator to predict short-term outcomesDavid Jiménez, Álvaro Dubois-Silva, Pablo Demelo-Rodríguez, et al.
Pageof 15